SYKT Alleviates Doxorubicin-Induced Cardiotoxicity via Modulating ROS-Mediated p53 and MAPK Signal Pathways

<div>SYKT inhibits DOX-induced MAPK activation. (A) DOX induces p38/JNK MAPK activation in a time-dependent manner. (B) DOX-mediated p38/JNK MAPK activation is inhibited by SB 203580/SP600125 and by SYKT. The cardiomyocytes were treated with SB 203580/SP600125 prior to DOX (1 <i>μ</i>M for 30 min) addition. <i>β</i>-Actin was used as an internal control. <sup>a</sup><i>p</i> &lt; 0.05 versus control; <sup>b</sup><i>p</i> &lt; 0.05 versus DOX;<i> n</i> = 6.</div>

Evidence-Based Complementary and Alternative Medicine

fig3

Figure 3

Figure 3: SYKT Alleviates Doxorubicin-Induced Cardiotoxicity via Modulating ROS-Mediated p53 and MAPK Signal Pathways 